VICO — Vicore Pharma Holding AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK1.82bn
- SEK1.34bn
Annual cashflow statement for Vicore Pharma Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -94 | -150 | -295 | -291 | -322 |
| Depreciation | |||||
| Non-Cash Items | 2.01 | 6.2 | 2.1 | 10.6 | 62 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.66 | 23.4 | 27.5 | -19.8 | 6.54 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -87 | -120 | -265 | -300 | -250 |
| Capital Expenditures | -0.147 | -3 | 0 | -3 | 0 |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -77 | 7 | -7 | 77 | -144 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -77.1 | 4 | -7 | 74 | -144 |
| Financing Cash Flow Items | -7.58 | -10.4 | -17.6 | -12.7 | -29.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 127 | 177 | 318 | 187 | 471 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -37.1 | 61 | 45.6 | -37.4 | 76.8 |